» Articles » PMID: 15232137

The Use of KIT and Tryptase Expression Patterns As Prognostic Tools for Canine Cutaneous Mast Cell Tumors

Overview
Journal Vet Pathol
Date 2004 Jul 3
PMID 15232137
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Cutaneous mast cell tumors (MCTs) are one of the most common tumors in dogs. Currently, prognostic and therapeutic determinations for MCTs are primarily based on the histologic grade of the tumor, but a vast majority of MCTs are of an intermediate grade, and the prognostic relevance is highly questioned. A more detailed prognostic evaluation, especially of grade 2 canine MCTs, is greatly needed. To evaluate the prognostic significance of KIT and tryptase expression patterns in canine cutaneous MCTs, we studied 100 cutaneous MCTs from 100 dogs that had been treated with surgery only. The total survival and disease-free survival time and the time to local or distant recurrence of MCTs were recorded for all dogs. Using immunohistochemistry, 98 of these MCTs were stained with anti-KIT and antitryptase antibodies. Three KIT- and three tryptase-staining patterns were identified. The KIT-staining patterns were identified as 1) membrane-associated staining, 2) focal to stippled cytoplasmic staining with decreased membrane-associated staining, and 3) diffuse cytoplasmic staining. The tryptase-staining patterns were identified as 1) diffuse cytoplasmic staining, 2) stippled cytoplasmic staining, and 3) little to no cytoplasmic staining. Based on univariate and multivariate survival analysis, increased cytoplasmic KIT staining was significantly associated with an increased rate of local recurrence and a decreased survival rate. The tryptase-staining patterns were not significantly associated with any survival parameter. On the basis of these results, we propose a new prognostic classification of canine cutaneous MCTs, according to their KIT-staining pattern, that can be used for the routine prognostic evaluation of canine cutaneous MCTs.

Citing Articles

Congenital neoplasms in cattle: A literature review and multi-institutional case series.

Sosa E, Giannitti F, Macias-Rioseco M, Colque Caro L, Silveira C, Garcia J J Vet Diagn Invest. 2025; :10406387251324512.

PMID: 40070027 PMC: 11904926. DOI: 10.1177/10406387251324512.


Clinical outcomes of dogs with high-grade cutaneous mast cell tumors.

Ong S, McKenna C, Pinard C, Richardson D, Oblak M Front Vet Sci. 2025; 11:1519636.

PMID: 39906044 PMC: 11790574. DOI: 10.3389/fvets.2024.1519636.


Oxidative Status and Lipid Metabolism Analytes in Dogs with Mast Cell Tumors: A Preliminary Study.

Ginoudis A, Pardali D, Mylonakis M, Tamvakis A, Tvarijonaviciute A, Lymperaki E Antioxidants (Basel). 2025; 13(12.

PMID: 39765802 PMC: 11672985. DOI: 10.3390/antiox13121473.


Investigation of the Theragnostic Role of KIT Expression for the Treatment of Canine Mast Cell Tumors with Tyrosine Kinase Inhibitors.

De Biase D, De Leo M, Piegari G, dAquino I, Di Napoli E, Mercogliano C Vet Sci. 2024; 11(10).

PMID: 39453084 PMC: 11512316. DOI: 10.3390/vetsci11100492.


Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.

Zmorzynski S, Kimicka-Szajwaj A, Szajwaj A, Czerwik-Marcinkowska J, Wojcierowski J Genes (Basel). 2024; 15(1).

PMID: 38275618 PMC: 10815783. DOI: 10.3390/genes15010137.